ClinicalTrials.gg
Not yet recruitingNCT07152184DREAMS-PhenUpdated May 26, 2026

Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach

A Phase 2 interventional study of Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup in Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology and Schizophrenia Spectrum and Other Psychotic Disorders, sponsored by University Hospital, Strasbourg, France. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by University Hospital, Strasbourg, France · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective of this study is to respond to frequent requests from patients who wish to reduce or even stop their antipsychotic treatment once they have achieved clinical stability. Psychiatrists are reluctant to respond to these requests because the method for safely reducing or stopping antipsychotic treatment remains poorly understood.

The investigators want to verify the existence of an interaction between treatment strategy and psychotic phenotype (cycloid psychosis vs. non-CP), i.e., in terms of functional remission, the benefit of the dose reduction strategy compared to the maintenance strategy will be greater in the CP group than in the non-CP group.

To this end, patients will be randomly assigned to four groups based on their phenotype and treatment strategy (CP-dose reduction; CP-dose maintenance; non-CP-dose reduction; and non-CP-dose maintenance).

Several hospitals throughout France are participating in this study, in which a random draw (called randomization) will be conducted to determine whether the physician will propose reducing the antipsychotic dose or maintaining it at the same dose for the patient.

Patients included in this study will be adults aged 18 to 60 who have been diagnosed with a schizophrenic spectrum disorder (SS): schizophrenia, schizophreniform disorder, schizoaffective disorder, or brief psychotic episode.

The antipsychotics studied are:

  • second-generation antipsychotics: amisulpride, aripiprazole, olanzapine, quetiapine, risperidone;
  • first-generation antipsychotics: chlorpromazine, flupentixol, haloperidol, levomepromazine, loxapine, pipotiazine, zuclopenthixol.

    288 patients will be included and followed for 24 months. The inclusion period is 48 months.

Fourteen follow-up visits are planned, every month for four months and then every two months. During these visits, self-questionnaires or cognitive tests will have to be completed by the patient, the caregiver, and/or the treating psychiatrist.

Three blood samples will be taken at inclusion, at 6 months, and at the end of the study, in particular to measure the level of medication in the blood.

02

Conditions studied

  • Patient With Schizophrenia Spectrum Disorder
  • NLM Classification WM 203, Psychology:Schizophrenic Psychology
  • Schizophrenia Spectrum and Other Psychotic Disorders
03

In context

Schizophrenia Spectrum and Other Psychotic Disorders

86 studies on the registry are indexed under Schizophrenia Spectrum and Other Psychotic Disorders; 14 are open to participants now.

This study's planned enrollment of 288 is above the median of 90 across 69 interventional studies indexed under Schizophrenia Spectrum and Other Psychotic Disorders.

Browse Schizophrenia Spectrum and Other Psychotic Disorders studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Patient 18-60 years of age;
  • Patient affiliated to health insurance (beneficiary or beneficiary's family);
  • Patient informed of the results of the preliminary medical examination;
  • Patient able to understand the aims and risks of the research (assisted by his/her curator, if applicable (if subject under curatorship*))
  • signed by patient
  • Patient with a diagnosis of schizophrenia spectrum disorder (SSD): schizophrenia, schizophreniform, schizoaffective disorder or brief psychotic episode according to ;
  • Patient with:

    1. Either a cycloid psychosis (CP) phenotype according to By-CP (score >=80%)
    2. Or another (non-CP) psychotic phenotype; (By-CP score \< 80%)
  • Outpatient followed by an ambulatory psychiatrist;
  • Patient with an identified caregiver, defined as a person able to support the patient for the duration of the study, spending at least 8 hours per week with the patient or having easy access to the patient per phone.
  • Patient clinically stabilized, for at least 6 months, as defined by

    a) low intensity of positive symptoms, i.e. PANSS P1, P2 and P3 items \< 4.

  • Patient treated with oral antipsychotics (in mono or polytherapy, with second- or first-generation antipsychotics);
  • Patients with a PSP score >70 at baseline will also be included
  • The participant agrees to follow the requirements detailed in the protocol *Subjects under limited guardianship (i.e. French "curatelle") can participate to the study.

Exclusion criteria

Exclusion Criteria:

  • - Patient hospitalized in a psychiatric ward;
  • Patient with a recent psychotic episode (during the last 6 months);
  • Patient treated with long-acting injection of antipsychotics (due to feasibility constraints and to the fact that these treatments remain essentially proposed to non-compliant patients with high risk of acute cessation and loss to follow-up);
  • Patient treated with clozapine (in mono or polytherapy - highly resistant patients, specificities of the relapses under clozapine
  • Patient considered by his psychiatrists to be at serious risk of harm to self or others (e.g. previous aggressive or suicidal behaviors); notably, a patient answering "yes" to C-SSRS suicidal ideation Type 4 or 5, having any suicidal behavior assessment within 6 months at Screening, or having been hospitalized or treated for suicidal behavior in the past 5 years before Screening. The investigator will rely on the results of the C-SSRS questionnaire completed at the time of inclusion (after consent has been signed) or previously completed as part of the patient's follow-up according to current practice.
  • Neurological or severe medical condition other than psychosis;
  • Pregnancy (verified by urinary test at enrollment for women of );
  • Current breastfeeding;
  • Patient involved in another Medicinal Product trial or having participated in another investigational drug trial, in which they received the investigational drug, within 60 days
  • Patient in an exclusion period defined by another research protocol;
  • Patient under guardianship (i.e. French 'tutelle');
  • Patient with care under constraint
  • Patients deprived of freedom because of a judicial measure.
  • Inability to give the patient the written consent form (emergency situation)
  • Patients with major depressive disorder (CDSS > 5) or manic episode ()
  • Patients with any of the following signs of substance abuse:

    1. Current diagnosis or history of substance use disorder and/or substance intoxication as defined in the DSM-5-TR. If the history of substance use disorder is more than 12 months before baseline, the participant may be allowed to enroll in the trial after consultation with the sponsor (Participant must also have negative urine drug screen at the screening.)
    2. A positive urine screen for drugs of abuse at screening.
    3. A history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer [354 mL/12 oz], wine or sake [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).
    4. A positive Breathalyzer test for alcohol at screening. The investigator will screen urine for drug abuse and perform an alcohol test at the inclusion visit (after consent has been signed), and may also rely on previous results obtained in the course of patient follow-up according to standard practice.
  • The participant is a trial site employee, a site employee's immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a site employee who is involved in conduct of this trial or may consent under duress.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    Patients with Cycloid Psychosis receiving the Dose Reduction strategy (CP-DR)

    After verifying the patient's phenotype, only those with cycloid psychosis will be included in this arm. The patient's usual antipsychotic dose will be gradually reduced to doses lower than those recommended by the marketing authorization (AMM).

    Drug: Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup

  • Active comparator
    Patients with Cycloid Psychosis receiving the Maintenance Treatment strategy (CP-MT)

    After verifying the patient's phenotype, only those with cycloid psychosis will be included in this arm. The patient's usual antipsychotic dose will be maintained in accordance with those recommended by the marketing authorization (AMM).

    Drug: Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup

  • Experimental
    Patients with Non-Cycloid Psychosis receiving the Dose Reduction strategy (Non-CP-DR)

    After verifying the patient's phenotype, only those without cycloid psychosis will be included in this arm. The patient's usual antipsychotic dose will be gradually reduced to doses lower than those recommended by the marketing authorization (AMM).

    Drug: Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup

  • Active comparator
    patients with Non-Cycloid Psychosis receiving the Maintenance Treatment strategy (Non-CP-MT)

    After verifying the patient's phenotype, only those without cycloid psychosis will be included in this arm. The patient's usual antipsychotic dose will be maintained in accordance with those recommended by the marketing authorization (AMM).

    Drug: Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup

Interventions

  • DrugUse of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup

    Biological A blood sample of up to 5 mL will be taken at visits V0, V5, and V14, for a maximum total volume of 15 mL for the study. Behavioral Quality of life and disease assessment questionnaires will need to be completed by the patient and their caregiver.

06

What researchers measure

Primary outcomes

  1. Percentage of patients with functional remission as defined by a Personal and Social Performance Scale score >70 (minimal 1 max 100) at 24 months follow-up (study endpoint).

    The Personal and Social Performance will be assessed at different times of the study, both by the treating psychiatrist of the patients (i.e. who is not blind to patients' treatment arm) and by the Dreams-Phen evaluation team (who will be blind to patients' treatment arm). The primary endpoint will rely ONLY on the PSP scores at 24 months assessed by the Dreams-Phen evaluation team. This evaluation will be performed during a webmeeting with the patient and his/her caregiver and will be based on the patient's functioning during the month preceding the evaluation.

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Berna F, Horowitz MA, Javelot H, Meyer N, Foucher JR. DREAMSPHEN: a randomised controlled study comparing dose reduction of antipsychotics vs maintenance treatment in schizophrenia spectrum disorder after stratification based on patients' psychotic phenotype - study protocol of a personalised medicine approach. BMJ Open. 2026 Jun 12;16(6):e117593. doi: 10.1136/bmjopen-2026-117593. PubMed 42285570 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Feb 2032, 64 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Sep 3, 2025
StartEst.
Oct 1, 2026
Primary completionEst.
Feb 1, 2032
CompletionEst.
Feb 1, 2032
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07152184
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Oct 1, 2026 (estimated)
Primary completion
Feb 1, 2032 (estimated)
Completion
Feb 1, 2032 (estimated)
Last update
May 26, 2026

Study contacts

Fabrice BERNA, MD
Contact
fabrice.berna@chru-strasbourg.fr
+33388116462

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion